Funding agencies: This work was funded by the National Institute of Neurological Disorders and Stroke Intramural Research Program.
Alcohol challenge and sensitivity to change of the essential tremor rating assessment scale
Article first published online: 7 OCT 2013
© 2013 International Parkinson and Movement Disorder Society
Volume 29, Issue 4, pages 555–558, April 2014
How to Cite
Voller, B., Lines, E., McCrossin, G., Artiles, A., Tinaz, S., Lungu, C., Hallett, M. and Haubenberger, D. (2014), Alcohol challenge and sensitivity to change of the essential tremor rating assessment scale. Mov. Disord., 29: 555–558. doi: 10.1002/mds.25667
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 3 APR 2014
- Article first published online: 7 OCT 2013
- Manuscript Accepted: 12 AUG 2013
- Manuscript Revised: 20 JUL 2013
- Manuscript Received: 7 MAY 2013
- essential tremor;
- assessment scale;
- clinical rating;
- alcohol challenge;
- validation study
The ability of the Essential Tremor (ET) Rating Assessment Scale (TETRAS) to detect changes in tremor severity is unknown.
Fifteen adult ET patients received a single oral ethanol dose calculated to reach 0.05 g/dL breath alcohol content (brAC). Effects were investigated independently with accelerometry and TETRAS.
Accelerometry data were log-transformed and a cumulative score logACC(R+L) was calculated. Correlation between logACC(R+L) and TETRAS was significant. TETRAS and accelerometry showed a significant effect of time point using repeated-measures analysis of variance. The difference between baseline and each of the following six time points as well as the correlation of TETRAS with brAC were significant. The calculated minimum detectable change of TETRAS was 8.9% and the effect size was d = 4.75 (95% confidence interval: 3.60–5.90).
We demonstrated sensitivity to change of the TETRAS performance scale after a therapeutic intervention, which further establishes its potential for use in both clinical and research settings. © 2013 International Parkinson and Movement Disorder Society